RxDoctor Payments Data

Manuel Espinel, MD

Internal Medicine · Delray Beach, FLNPI 1730399437

Payments from drug & device makers

$20,169in general payments, 2019–2025

Across 452 payments — averaging $44.62 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$4K
  • AstraZeneca$2K
  • Johnson & Johnson$2K
  • GSK$2K
  • Novo Nordisk$1K
  • Lilly USA, LLC$1K
  • plus $9K from 34 others

What the payments were for

  • Food & beverage$20,169100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$20,169 in reported general payments places this provider in the 95th percentile of 8,530 internal medicine providers in Florida.

See all internal medicine providers in Florida

Medicare billing

Part B allowed, 2024
$429,161
Medicare patients
837
Services billed
5,547

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide206$239,061
EliquisApixaban361$202,098
MounjaroTirzepatide142$171,013
FarxigaDapagliflozin Propanediol149$147,042
XareltoRivaroxaban121$87,649
JardianceEmpagliflozin69$80,681
IngrezzaValbenazine Tosylate13$49,873
Repatha SureclickEvolocumab47$49,097
Trelegy ElliptaFluticasone/Umeclidin/Vilanter61$47,589
GemtesaVibegron24$22,984
LinzessLinaclotide19$18,591
VascepaIcosapent Ethyl32$18,192
EntrestoSacubitril/Valsartan19$17,942
BrilintaTicagrelor19$15,940
KerendiaFinerenone14$14,995

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$1,184$239,061206 claims
PfizerEliquis$253$202,098361 claims
Lilly USA, LLCMounjaro, Trulicity$1,105$181,713157 claims
AstraZenecaFarxiga, Brilinta$2,129$162,982168 claims
Johnson & JohnsonXarelto$1,777$87,649121 claims
Boehringer IngelheimJardiance$257$80,68169 claims
GSKTrelegy Ellipta$1,681$47,58961 claims
AbbVieLinzess, Qulipta, Synthroid$265$36,22890 claims
Sumitomo Pharma America, Inc.Gemtesa$155$22,98424 claims
NovartisEntresto$871$17,94219 claims
BayerKerendia$482$14,99514 claims
MerckJanuvia$37$13,44613 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 8,530 internal medicine providers in Florida.

Other internal medicine in Delray Beach

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →